![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
Sponsors and Collaborators: |
Robert H. Lurie Cancer Center National Cancer Institute (NCI) |
---|---|
Information provided by: | National Cancer Institute (NCI) |
ClinicalTrials.gov Identifier: | NCT00004895 |
RATIONALE: Palliative therapy with octreotide may help patients who have bowel obstruction that cannot be removed by surgery to live longer and more comfortably.
PURPOSE: Phase II trial to study the effectiveness of octreotide as palliative therapy in treating patients who have cancer-related bowel obstruction that cannot be removed by surgery.
Condition | Intervention | Phase |
---|---|---|
Colorectal Cancer Constipation, Impaction, and Bowel Obstruction Extrahepatic Bile Duct Cancer Gastric Cancer Gastrointestinal Stromal Tumor Nausea and Vomiting Ovarian Cancer Pancreatic Cancer Peritoneal Cavity Cancer Small Intestine Cancer |
Drug: octreotide acetate |
Phase II |
Study Type: | Interventional |
Study Design: | Supportive Care |
Official Title: | Octreotide for Palliation of Inoperable Bowel Obstruction: A Phase II Study |
Study Start Date: | October 1999 |
OBJECTIVES:
OUTLINE: Patients receive octreotide subcutaneously or IV over 24 hours on days 2-5.
Patients who respond well to study may continue octreotide for palliative effects.
PROJECTED ACCRUAL: A total of 9-25 patients will be accrued for this study over 9 months.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
PATIENT CHARACTERISTICS:
Age:
Performance status:
Life expectancy:
Hematopoietic:
Hepatic:
Renal:
Other:
PRIOR CONCURRENT THERAPY:
Biologic therapy:
Chemotherapy:
Endocrine therapy:
Radiotherapy:
Surgery:
United States, Illinois | |
Robert H. Lurie Comprehensive Cancer Center, Northwestern University | |
Chicago, Illinois, United States, 60611-3013 |
Study Chair: | J. Cameron Muir, MD | Robert H. Lurie Cancer Center |
Study ID Numbers: | CDR0000067573, NU-97X1, NCI-G00-1685 |
Study First Received: | March 7, 2000 |
Last Updated: | May 9, 2009 |
ClinicalTrials.gov Identifier: | NCT00004895 History of Changes |
Health Authority: | United States: Federal Government |
stage I colon cancer stage II colon cancer stage III colon cancer stage IV colon cancer stage I gastric cancer stage II gastric cancer stage III gastric cancer stage IV gastric cancer recurrent gastric cancer stage I pancreatic cancer stage II pancreatic cancer stage III pancreatic cancer stage IV pancreatic cancer recurrent pancreatic cancer stage I rectal cancer |
stage II rectal cancer stage III rectal cancer stage IV rectal cancer recurrent colon cancer recurrent rectal cancer stage I ovarian epithelial cancer stage II ovarian epithelial cancer stage III ovarian epithelial cancer stage IV ovarian epithelial cancer recurrent ovarian epithelial cancer small intestine adenocarcinoma small intestine lymphoma small intestine leiomyosarcoma localized extrahepatic bile duct cancer unresectable extrahepatic bile duct cancer |
Signs and Symptoms, Digestive Rectal Neoplasms Pancreatic Neoplasms Colonic Diseases Octreotide Urogenital Neoplasms Rectal Diseases Ileal Diseases Duodenal Neoplasms Intestinal Obstruction Peritoneal Diseases Ovarian Cancer Endocrine Gland Neoplasms Digestive System Neoplasms Antineoplastic Agents, Hormonal |
Genital Neoplasms, Female Endocrine System Diseases Bile Duct Diseases Gastrointestinal Neoplasms Pancreatic Diseases Stomach Cancer Bile Duct Neoplasms Vomiting Gastrointestinal Diseases Leiomyosarcoma Gonadal Disorders Ovarian Diseases Bile Duct Cancer, Extrahepatic Genital Diseases, Female Signs and Symptoms |
Signs and Symptoms, Digestive Pancreatic Neoplasms Colonic Diseases Octreotide Urogenital Neoplasms Rectal Diseases Ileal Diseases Intestinal Obstruction Duodenal Neoplasms Neoplasms by Site Therapeutic Uses Peritoneal Diseases Endocrine Gland Neoplasms Digestive System Neoplasms Antineoplastic Agents, Hormonal |
Genital Neoplasms, Female Endocrine System Diseases Neoplasms Bile Duct Diseases Gastrointestinal Neoplasms Pancreatic Diseases Bile Duct Neoplasms Vomiting Gastrointestinal Diseases Gonadal Disorders Antineoplastic Agents Ovarian Diseases Genital Diseases, Female Signs and Symptoms Stomach Diseases |